Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 8 of 8 publications.
Skip to main content
Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the HSG 2022 Annual Meeting; November 2022. Tampa, FL. [abstract] J Huntingtons Dis. 2022 Oct 31; 11(s1):S31. Previously presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting. doi: 10.3233/JHD-229005
Lopez LR, Ahn J-H, Alves T, Arthur JC. Microenvironmental factors that shape bacterial metabolites in inflammatory bowel disease. Front Cell Infect Microbiol. 2022 Jul 15;12:934619. doi: 10.3389/fcimb.2022.934619
Hoffman V, Xue F, Ezzy SM, Yusuf A, Green E, Eisele O, Kurth T, Seeger JD. Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine receiving prophylactic treatments: an observational cohort study. Cephalalgia. 2019 Oct;39(12):1544-59. doi: 10.1177/0333102419856630
Hoffman V, Xue F, Ezzy SM, Yusuf A, Green E, Eisele O, Kurth T, Seeger JD. Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine treated with prophylactic medications: an observational cohort study. Cephalalgia. 2019 Oct;39(12):1544-59. doi: 10.1177/0333102419856630
Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019 Oct;39(12):1518-34. doi: 10.1177/0333102419851855
Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150
Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.
Burch SP, Davis KH, Fehnel SE, Nelsen AC, Hill CD, Shashidhar KH. Outcomes, impact and behavior associated with acute treatment of migraine. Poster presented at the 16th Migraine Trust International Symposium; November 2006. [abstract] Cephalalgia. 2006 Nov; 26(11):1358-403.